OneSource Specialty Pharma: Market Brief (January 2026) **OneSource Specialty Pharma** shares faced intense selling pressure this week, plummeting **18%** to an intraday low of roughly **Rs 1,178**. The sell-off was triggered by a dismal third-quarter performance for FY26, driven by regulatory bottlenecks in key North American markets. **Financial Hit (Q3 FY26)** The company reported a consolidated net loss of **Rs 47 crore** (adjusted PAT), a sharp reversal from the profit recorded in the same period last year. Revenue took a massive hit, dropping **26%** year-on-year to **Rs 290 crore** (down from **Rs 393 crore**). Operating performance also suffered, with EBITDA collapsing **88%** to just **Rs 17 crore**. Consequently, EBITDA margins shrank dramatically to **6%**, losing over **3,000 basis points** compared to the healthy **36%** margin seen a year ago. **The Trigger: Canada Delay** The primary drag on performance was the delayed regulatory approval for **semaglutide** in **Canada**. OneSource acts as the manufacturing partner for **Dr. Reddy's Laboratories** for this blockbuster diabetes and weight-loss drug. Because of the delay, the company could not convert its Master Service Agreement (MSA) into a more lucrative Commercial Supply Agreement (CSA) during the quarter. This stalled revenue recognition and left the company bearing a high fixed-cost base with reduced inflows. **FY28 Outlook Intact** Despite the "subdued" quarter, management has reaffirmed its aggressive long-term targets. The company maintains its FY28 guidance of **$400 million** in organic revenue, potentially rising to **$500 million** when including proposed acquisitions. CEO **Neeraj Sharma** emphasized that the order book remains robust and the biologics funnel is at a historic high. The company continues to target an EBITDA margin of **~40%** and a Return on Capital Employed (ROCE) above **50%** by FY28, expecting the regulatory hurdles to be temporary.